查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2052061

肝炎檢測市場－市場趨勢、競爭格局和市場預測（2034 年）

Hepatitis Testing - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

肝炎檢測市場概述

  • 全球肝炎檢測市場預計將從 2025 年的 34.7008 億美元成長到 2034 年的 57.8524 億美元，展現出強勁且持續的成長動能。
  • 全球肝炎檢測市場預計在 2026 年至 2034 年的預測期內將以 5.93% 的年複合成長率成長。
  • 肝炎檢測市場的主要驅動力是肝炎感染率的上升以及相關風險因素的增加，例如慢性肝病、文明病和高風險族群。隨著早期檢測意識的提高，醫療專業人員擴大採用就地檢驗，以實現快速現場診斷和及時治療決策。此外，診斷設備製造商不斷進行產品研發和創新，特別是推出先進的分子檢測方法、快速診斷試劑盒和自動化檢測平台，提高了肝炎檢測的可及性和效率，進一步推動了市場成長。
  • 在肝炎檢測市場中運作的主要公司包括 Abbott、F. Hoffmann-La Roche Ltd.、Diasorin SpA、Bio-Merieux、Hologic Inc.、Danaher Corporation、AdvaCare Pharma、Alpine Biomedicals Pvt Ltd.、Siemens Healthineers、SD Biosensor, Inc.、OraSure Technologies Inc.nos、Cectics, D.Snos、Aec） Inc.、BTNX Inc.、ACON Laboratories, Inc.、Altona Diagnostics GmbH、Bruker Corporation、Mikrogen GmbH 和 Fortress Diagnostics。
  • 北美肝炎檢測市場的主要驅動力是慢性B型和C型肝炎的高發生率，這持續推動對早期診斷和定期疾病監測的需求。此外，分子診斷、自動化免疫檢測和快速就地檢驗等技術的進步顯著提高了檢測的準確性、效率和可及性。強制性捐血篩檢計畫和公眾肝臟健康意識的提高也促進了檢測需求的持續成長。這些因素共同作用，正在加強和加速北美肝炎檢測市場的成長。
  • 在按產品類型分類的肝炎檢測市場中，試劑和試劑盒類別預計在 2025 年將佔據最大的市場佔有率。

推動肝炎檢測市場成長的因素

  • 肝炎感染率上升及相關危險因子：肝炎檢測市場主要受肝炎感染率上升以及肝癌和肝硬化等嚴重併發症發生率增加的驅動。慢性B型和C型肝炎病毒感染會隨著時間的推移造成進行性肝損傷，顯著增加肝硬化和肝癌的風險。日益加重的健康負擔使得早期發現和定期篩檢至關重要，從而能夠及時干預並更好地管理疾病。因此，對分子檢測、血清學檢測和快速診斷試劑盒等先進肝炎診斷工具的需求不斷成長，這推動了全球肝炎檢測市場的整體擴張。
  • 捐血和血液篩檢計畫的擴展顯著推動了捐血篩檢市場的發展，因為捐血的血液需要經過嚴格篩檢，以防止乙型和丙型肝炎等感染疾病的傳播。血庫和輸血中心在核准血液用於輸血之前，都會常規進行必要的篩檢，以檢測肝炎抗原、抗體或病毒核酸。隨著醫療需求、手術和急診治療的增加，捐血也隨之增加，對可靠的肝炎檢測方法（例如酶聯免疫吸附試驗 (ELISA)、快速診斷檢測和核酸增幅檢查(NAT)）的需求也日益成長。此外，政府法規和公共衛生舉措強制要求嚴格執行血液安全規程，進一步加速了肝炎診斷試劑盒和試劑的普及，從而促進了肝炎檢測市場的整體成長。
  • 公眾意識提升與篩檢計畫擴大：隨著各國政府和醫療機構積極推廣肝炎感染的早期檢測，公眾意識的提升和篩檢計畫的擴大顯著推動了肝炎檢測市場的發展。公共衛生宣傳活動、社區篩檢活動以及國家肝炎防治計畫都在鼓勵定期檢測，尤其針對高風險族群。早期診斷有助於及時治療並防止疾病傳播，從而增加了對各種肝炎診斷檢測的需求，包括酶聯免疫吸附試驗（ELISA）、快速檢測和分子檢測。因此，公眾意識的宣傳活動和大規模篩檢計畫的擴大正在推動肝炎檢測市場的成長。
  • 擴大即時檢測的覆蓋範圍：即時肝炎檢測套組的日益普及，使得診斷服務更加便捷，尤其是在開發中國家和偏遠醫療機構。快速診斷檢測使醫護人員無需複雜的檢查室設備即可在幾分鐘內獲得結果。這種分散式檢查的推廣有助於提高篩檢覆蓋率並加速市場成長。
  • 主要市場參與企業活性化產品研發投入：診斷設備製造商不斷加大研發投入，致力於開發速度更快、更準確、更易用的先進檢測解決方案。這包括推出高靈敏度分子檢測方法、快速診斷試劑盒、自動化檢測平台和多重檢測技術。這些發展不僅提高了肝炎檢測的效率，也拓展了醫院、檢查室和即時檢測點可用的檢測選擇範圍。因此，主要參與者對創新的持續關注加劇了市場競爭，並推動了肝炎檢測市場的整體成長。

肝炎檢測市場報告細分

本肝炎檢測市場報告全面概​​述了全球肝炎檢測市場，重點分析了關鍵趨勢、成長要素、挑戰和機會。報告涵蓋了詳細的市場細分，包括產品類型（試劑盒、試劑盒和儀器）、技術（酵素免疫分析法(ELISA)、快速診斷測試、聚合酵素鏈鎖反應(PCR)、化學冷光免疫檢測(CLIA) 等）、疾病類型（乙型、丙型、甲型、丁型和戊型肝炎）、檢測類型（抗原檢測、抗體檢測實驗室、用戶檢測和診所）。報告深入分析了北美、歐洲和亞太等主要市場的競爭格局、監管環境和市場動態，並詳細介紹了主要行業參與企業和近期產品創新，為企業提供關鍵數據，以識別市場潛力、制定戰略計劃並把握快速成長的肝炎檢測市場中的新興機會。

肝炎檢測是一系列用於檢測肝炎病毒及其引起的肝損傷的醫學診斷程序。通常，透過血液檢測來識別病毒抗原、抗體或遺傳物質（DNA/RNA），以確定受檢者目前是否感染、先前是否感染或是否患有慢性感染。這些檢測有助於早期診斷、監測疾病進展、制定治療方案以及預防肝炎感染。

肝炎檢測市場的主要驅動力是肝炎感染率的上升以及肝硬化和肝癌等嚴重併發症發生率的增加。這提高了早期診斷和定期篩檢的需求。此外，捐血的增加和強制性血液篩檢計畫的擴展也顯著提高了對肝炎診斷檢測的需求，以確保輸血安全。加強宣傳活動和全國性篩檢計畫也透過鼓勵個人，特別是高風險族群進行早期檢測，促進了市場成長。此外，即時檢測的普及提高了人們獲得快速可靠診斷的機會，尤其是在偏遠地區和資源匱乏的環境中。同時，診斷公司不斷進行產品開發和技術進步，包括推出分子檢測、自動化免疫檢測和快速診斷試劑盒，提高了檢測的準確性和效率，最終推動了整個肝炎檢測市場的成長。

肝炎檢測市場的最新市場動態和趨勢是什麼？

肝炎檢測市場受到乙型和丙型肝炎盛行率上升以及對早期診斷和定期監測的需求不斷成長的推動。

據美國疾病管制與預防中心（CDC，2025）稱，病毒性肝炎影響全球超過3億人。

此外，根據相同資訊來源統計，2022年新增B型肝炎病毒（HBV）感染者120萬人，新增C型肝炎病毒（HCV）感染者100萬人。約有2.54億人患有慢性B型肝炎，約有5000萬人患有慢性C型肝炎。隨著乙型和丙型肝炎感染人數的增加，對早期診斷、定期篩檢和持續疾病監測的需求顯著上升。尤其是在高風險族群中感染率的上升，促使各國政府和醫療機構擴大篩檢計畫並實施有針對性的公共衛生措施。此外，有效抗病毒療法的出現使得早期發現對於及時干預至關重要，這進一步促進了檢測的普及，並推動了整個肝炎檢測市場的成長。

此外，印度於2018年啟動的「國家病毒性肝炎預防和控制計畫」顯著擴大了全國範圍內的肝炎篩檢和治療力度，其目標是在2030年前消滅肝炎並根除丙型肝炎。報告顯示，截至2024年7月，該計畫已對約1.034億人進行了乙型和丙型肝炎篩檢，並自啟動以來為約33萬名患者提供了治療。該計畫進行的數百萬次乙型和丙型肝炎篩檢，大大增加了醫院、檢查室和社區健康中心對診斷試劑、試劑盒和檢測套組的需求。此類政府主導的篩檢計畫透過推廣定期檢測、提高疾病檢出率和擴大肝炎診斷技術的應用，促進了肝炎篩檢市場的整體成長。

此外，捐血和血液篩檢計畫的擴展顯著推動了肝炎檢測市場的發展，因為所有捐血的血液都需要經過嚴格篩檢，以防止乙型和丙型肝炎等感染疾病的傳播。根據世界衛生組織（WHO）提供的數據（2026年），全球整體捐血。因此，隨著全球捐血量的增加，對可靠的肝炎診斷檢測（包括酵素連結免疫吸附試驗（ELISA）、核酸檢測（NAT）和快速診斷試劑盒）的需求也隨之成長。

然而，產品研發活動的增加進一步推動了呼吸照護設備市場的整體成長。例如，2024年6月，Cepheid公司宣布其Xpert® HCV檢測產品已獲得FDA的全新上市核准和《臨床實驗室改進法案》(CLIA)核准。這使得該產品成為美國唯一一款能夠直接從人類毛細血管全血（指尖血）檢體中檢測丙型C型肝炎病毒RNA的分子檢測產品。 Xpert HCV檢測採用GeneXpert Xpress系統進行。

因此，由於上述因素，預計從 2026 年到 2034 年的預測期內，丙型肝炎檢測市場整體將擴大。

然而，肝炎檢測市場面臨許多挑戰，可能阻礙其成長。血清學檢測的技術局限性，例如交叉反應、感染早期靈敏度低或受其他生物因素干擾等，會導致結果不準確或不確定，進而影響診斷和患者照護。此外，嚴格的監管核准流程需要大量的臨床檢驗並符合區域和國際標準，這可能會延遲產品上市並增加研發成本。這些因素綜合起來，可能對製造商和醫療機構構成重大障礙，從而限制肝炎檢測解決方案的廣泛應用和及時使用。

肝炎檢測市場區隔分析

數據按產品類型（試劑、試劑盒和儀器）、技術（酵素免疫分析法(ELISA)、快速診斷測試、聚合酵素鏈鎖反應(PCR)、化學冷光免疫檢測(CLIA) 等）、疾病類型（乙型肝炎、丙型肝炎、甲型肝炎、丁型肝炎和戊型肝炎）、測試類型（抗原測試、抗體測試、核酸測試和基因分型）、最終用戶（北美地區分類）、其他地區和其他診所（北美地區分類）、研究

肝炎檢測市場區域分析

北美肝炎檢測市場趨勢

預計到 2025 年，北美將佔所有地區中的最高比例，達到 42%。這一主導地位得益於乙型和丙型肝炎的高發病率、廣泛的篩檢措施、完善的醫療保健基礎設施、診斷技術的進步以及對捐血的強制性檢測。

根據美國疾病管制與預防中心（CDC）的數據，2023年美國報告了1643例甲型肝炎新病例、2212例乙型肝炎新發病例和5538例丙型肝炎新發病例。隨著全球乙型和丙型肝炎感染病例的增加，對早期診斷、定期篩檢和持續疾病監測的需求顯著成長。尤其考慮到高風險族群的高感染率，各國政府和醫療機構正在擴大篩檢計畫並實施有針對性的公共衛生措施。此外，有效抗病毒治療方法的廣泛應用使得早期發現至關重要，這反過來又推動了檢測量的增加和肝炎檢測市場的整體成長。

此外，根據藍仙女：艾德麗安·威爾遜肝癌協會（Blue Faery: The Adrienne Wilson Liver Cancer Association）估計，2024年全球將新增41,630例肝癌病例，其中男性28,000例，女性13,630例。慢性B型和C型肝炎病毒感染是罹患肝癌的主要危險因子。長期病毒性肝炎會導致肝炎、肝纖維化和肝硬化，增加罹癌風險。因此，隨著人們對早期診斷和監測的日益關注，對血清學檢測、分子檢測和快速診斷試劑盒等先進診斷工具的需求不斷成長，從而推動了全球肝炎檢測市場的擴張。

然而，不斷增加的產品研發活動進一步推動了整個肝炎檢測市場的發展。例如，2024年6月，Cepheid公司宣布其Xpert® HCV檢測產品獲得FDA的全新核准（De Novo）和《臨床實驗室改進法案》（CLIA）核准。這使得該產品成為美國唯一一款可以直接從人類毛細血管全血（指尖血）檢體中檢測C型肝炎病毒RNA的分子檢測產品。

因此，預計以上所有因素將在預測期內推動北美肝炎檢測市場的發展。

歐洲肝炎檢測市場趨勢

歐洲肝炎檢測市場的主要驅動力是乙型和丙型肝炎病毒感染的持續蔓延，這導致人們對早期檢測和定期監測的需求不斷成長。同時，分子診斷、自動化免疫檢測和快速就地檢驗等技術的進步，正在提高肝炎檢測的準確性和可近性。

根據歐洲疾病預防控制中心（ECDC）的數據，2023年歐盟/歐洲經濟區（EU/EEA）共報告了37,766例乙型肝炎病毒（HBV）感染病例，粗發病率為每10萬人8.1例。其中，6.3%為急性病例，40.5%為慢性病例，46.1%為病因不明，7.1%為未分類病例。隨著乙型和丙型肝炎病例數的增加，早期診斷、定期篩檢和持續疾病監測的需求顯著增加。有效抗病毒治療方法的廣泛應用進一步凸顯了早期檢測的重要性，促進了檢測的普及，並最終推動了肝炎檢測市場的發展。

此外，根據國際癌症研究機構（IARC）的數據，2025年歐洲新增肝癌和肝內膽管癌病例數估計為91,200例，預計到2045年將達到113,000例。早期發現肝炎感染對於預防其發展為包括肝癌和膽管癌在內的嚴重肝臟疾病至關重要。隨著人們對這種關聯的認知不斷提高，各國政府和醫療機構正在實施大規模篩檢項目，這推動了全球肝炎檢測市場的成長，因為對血清學檢測、分子檢測和快速就地檢驗的需求不斷增加。

因此，預計以上所有因素將在預測期內推動歐洲肝炎檢測市場的發展。

亞太地區肝炎檢測市場趨勢

在亞太地區，乙型和丙型肝炎感染率的上升以及政府主導的旨在早期診斷和疾病控制的各項舉措的擴大，正在推動肝炎檢測市場的發展。此外，分子檢測和快速就地檢驗等先進診斷技術的引入，也提高了肝炎檢測的可及性和效率。

根據全球肝炎消除計劃舉措）2022年的調查報告，日本慢性B型肝炎感染率估計為0.77%。同一個機構（2023年）估計，中國有760萬人患有慢性C型肝炎。隨著感染人數的持續成長，對早期診斷、定期篩檢和持續疾病監測的需求顯著增加。早期發現有助於及時啟動抗病毒治療，從而預防肝硬化和肝癌等嚴重併發症。因此，對早期準確診斷日益成長的需求正在加速肝炎檢測市場的擴張。

此外，根據國際癌症研究機構（IARC）的數據，預計到2025年，日本新增肝癌和肝內膽管癌病例將達到39萬例，到2045年將達到54.1萬例。由於長期感染肝炎病毒可導致肝炎、肝硬化，最終發展為癌症，因此，早期檢測和定期篩檢肝炎病毒的需求日益成長。由此，醫療專業人員擴大進行肝炎檢測，以便及早發現感染者並監測疾病進展，從而擴大了全部區域肝炎檢測市場。

然而，不斷增加的產品研發活動進一步推動了肝炎檢測市場的整體成長。例如，2025年10月，Hextar Healthcare旗下子公司、創新型快速診斷檢測套組製造商Reszon Diagnostics International推出了「RESZON HBsAg快速檢測試劑盒」。此檢測套組可快速可靠地檢測血清、血漿或全血檢體中的乙型肝炎表面抗原（HBsAg）。

因此，上述因素預計將推動全部區域肝炎檢測市場的擴張。

肝炎檢測市場的主要參與者有哪些？

以下是肝炎檢測市場的主要參與者。這些公司通常佔據最大的市場佔有率，並對行業趨勢產生影響。

  • Abbott
  • F. Hoffmann-La Roche Ltd
  • DiaSorin SpA
  • Bio-Merieux
  • Hologic, Inc.
  • Danaher Corporation
  • AdvaCare Pharma
  • Alpine Biomedicals Pvt Ltd
  • Siemens Healthineers
  • SD Biosensor, Inc.
  • OraSure Technologies, Inc.
  • Creative Diagnostics
  • SSI Diagnostica A/S
  • InTec Products, Inc.
  • BTNX Inc.
  • ACON Laboratories, Inc.
  • Altona Diagnostics GmbH
  • Bruker Corporation
  • Mikrogen GmbH
  • Fortress Diagnostics
  • 其他

競爭格局如何影響肝炎檢測市場？

肝炎檢測市場的競爭格局由全球診斷領導企業和新興區域公司共同構成，所有企業都在努力創新並擴大市場佔有率。羅氏診斷、雅培、西門子醫療和Bio-Rad等老字型大小企業憑藉包括ELISA試劑盒、分子檢測和快速就地檢驗在內的豐富產品系列，以及覆蓋多個地區的強大分銷網路和監管核准，在市場中佔據主導地位。持續的技術創新加劇了競爭，各公司都在大力投資下一代診斷技術，以實現高靈敏度、快速出結果和自動化，從而滿足日益成長的臨床需求。此外，策略聯盟、併購和夥伴關係也擴大被用於擴大地域覆蓋範圍、增強研發能力和改善新興市場的准入。中小型企業和專注於本地市場的公司則專注於經濟型快速檢測和專業分子檢測套組等細分領域，為終端用戶提供多樣化的選擇。這種充滿活力的競爭環境正在推動創新，提高檢測的準確性，擴大產品的供應範圍，並最終塑造全球肝炎檢測市場的成長軌跡。

總體而言，肝炎檢測市場競爭非常激烈，創新、合規和策略性成長舉措是企業脫穎而出、獲得市場佔有率並滿足全球醫療保健提供者不斷變化的需求的關鍵因素。

肝炎檢測市場近期發展趨勢

  • 2025 年 12 月，Altona 推出了“AltoStar® HDV RT-PCR Kit 1.5 (CE-IVD)”，完善了其涵蓋所有五種類型肝炎病毒的 CE-IVD PCR 產品線。
  • 2025 年 8 月，HiMedia Laboratories 的 Hi-PCR(R) 乙型和丙型肝炎分子診斷試劑盒（定量）獲得了印度中央藥品標準和監管局 (CDSCO) 的核准，這標誌著該公司肝炎檢測產品組合的一個重要里程碑。

肝炎檢測市場的市場區隔

  • 按產品類型分類的肝炎檢測市場
  • 試劑和試劑盒
  • 裝置
  • 肝炎檢測技術的組成
  • 酵素免疫分析法（ELISA）
  • 快速診斷測試
  • 化學冷光免疫檢測（CLIA）
  • 聚合酵素鏈鎖反應（PCR）
  • 其他
  • 肝炎檢測、疾病類型、暴露
  • B型肝炎
  • C型肝炎
  • 甲型肝炎
  • 頂客
  • 戊型肝炎
  • 肝炎檢測類型與感染途徑
  • 抗原檢測
  • 抗體檢測
  • 核酸
  • 基因分型
  • 肝炎檢測最終用戶暴露
  • 醫院和診所
  • 診斷檢測實驗室
  • 其他
  • 肝炎檢測的區域趨勢
  • 北美肝炎檢測市場
  • 美國肝炎檢測市場
  • 加拿大肝炎檢測市場
  • 墨西哥的肝炎檢測市場
  • 歐洲肝炎檢測市場
  • 英國肝炎檢測市場
  • 德國肝炎檢測市場
  • 法國肝炎檢測市場
  • 義大利肝炎檢測市場
  • 西班牙肝炎檢測市場
  • 其他歐洲國家的肝炎檢測市場
  • 亞太地區肝炎檢測市場
  • 中國的肝炎檢測市場
  • 日本肝炎檢測市場
  • 印度肝炎檢測市場
  • 澳洲肝炎檢測市場
  • 韓國肝炎檢測市場
  • 亞太地區其他肝炎檢測市場
  • 世界其他地區的肝炎檢測市場
  • 南美洲肝炎檢測市場
  • 中東肝炎檢測市場
  • 非洲肝炎檢測市場

影響分析

人工智慧驅動的創新與應用：

人工智慧驅動的創新正透過提高診斷準確性、營運效率和臨床決策能力，對肝炎檢測市場產生日益顯著的影響。人工智慧 (AI) 和機器學習演算法能夠分析來自影像、檢測結果和患者記錄的複雜數據，識別出人類難以單獨解讀的模式。在肝炎檢測領域，人工智慧能夠改善分子和血清學檢測數據的解讀，減少假陽性和假陰性，並實現感染的早期發現。人工智慧還能透過最佳化檢體處理、結果檢驗和品管，加速高通量檢查室環境中的工作流程自動化，進而縮短檢測結果報告時間並降低營運成本。人工智慧工具與數位免疫檢測和 PCR 系統等新一代診斷平台整合，幫助檢查室根據患者病歷和風險因素量身定做檢測方案，從而改善個人化診斷和治療方案的發展。此外，透過識別肝炎發生率和檢測模式的趨勢，人工智慧能夠促進預測分析和人群健康管理，使醫療系統能夠更有效地分配資源，並實施針對高風險族群的篩檢計畫。此外，人工智慧驅動的軟體支援遠端醫療和遠端解讀檢測結果，從而擴大了服務不足和資源匱乏地區的醫療服務覆蓋範圍。整體而言，將人工智慧融入肝炎檢測體系能夠提高效率、準確性和擴充性，使人工智慧成為推動未來市場成長和創新的變革力量。

美國關稅對肝炎檢測市場的影響分析：

美國關稅對肝炎檢測市場的影響主要體現在對進口醫療和診斷產品徵收的廣泛關稅將如何影響體外診斷（IVD）產業的成本、供應鍊和競爭力，包括肝炎檢測套組及相關試劑。由於許多診斷組件和完整的檢測套組均產自美國以外，因此，從基本關稅到針對主要製造地產品的高額貿易制裁，進口關稅可能會推高依賴海外生產的公司的銷貨成本，進而導致實驗室、診所和患者面臨更高的價格。診斷設備製造商可能會採取諸如自行承擔成本、將製造地轉移到美國或調整供應鏈等措施，這些措施可能會影響肝炎檢測產品的定價和供應鏈。關稅導致的投入成本增加和供應鏈中斷可能導致價格上漲，並使預測基本物資採購變得更加困難，從而可能加重醫療機構的營運預算負擔，並影響檢測數量和整體市場成長趨勢。如果依賴進口的競爭對手因關稅而面臨成本增加，那麼主要在國內生產的公司可能會從中受益。然而，關稅方面的持續不確定性可能會阻礙投資，並使肝炎檢測市場的供應商和買家的長期規劃變得複雜。

這項分析能為客戶帶來哪些好處？

  • 成本管理：透過了解關稅趨勢，客戶可以預測成本上漲，並據此調整定價策略，以確保盈利。
  • 供應鏈最佳化：透過尋找替代供應商並使其供應鏈多元化，客戶可以減少對高關稅地區的依賴，並增強業務永續營運。
  • 監管合規：專家指導幫助客戶應對不斷變化的法規環境，從而保持合規並避免潛在的法律挑戰。
  • 策略規劃：深入了解關稅的影響，使客戶能夠就製造地、夥伴關係和打入市場策略做出明智的決策。

肝炎檢測市場報告要點。

  • 目前肝炎檢測市場規模分析（2025 年）及 8 年市場預測（2026 年至 2034 年）
  • 過去三年發生的主要產品和技術開發、併購、合作和合資企業
  • 在肝炎檢測市場佔據主導地位的領導公司。
  • 肝炎檢測市場的其他競爭者也面臨各種機會。
  • 哪些細分市場在2025年表現最佳？這些細分市場在2034年又會呈現哪些趨勢？
  • 目前哪些地區、國家在肝炎檢測市場表現最佳？
  • 企業應專注於哪些地區或國家，以尋求肝炎檢測市場的未來成長機會？

關於肝炎檢測市場的常見問題

1. 肝炎檢測市場的成長率是多少？

  • 預計從 2026 年到 2034 年的預測期內，肝炎檢測市場將以 5.93% 的年複合成長率成長。

2. 針頭安全裝置的市場規模有多大？

  • 全球肝炎檢測市場預計將從 2025 年的 347008 億美元成長到 2034 年的 578524 億美元，表明市場將保持強勁且持續的成長。

3. 哪個地區在肝炎檢測市場中佔據最大的市佔率？

  • 北美肝炎檢測市場主要受慢性乙型和丙型肝炎高發生率的驅動，這導致早期診斷和定期監測的需求日益成長。分子診斷、自動化免疫檢測和快速檢測技術的進步，以及強制性血液篩檢和公眾意識的提高，都在提升檢測的準確性、可及性和市場需求，所有這些因素都促進了市場成長。

4. 肝炎檢測市場的成長要素為何？

  • 肝炎檢測市場的主要驅動力是肝炎感染率的上升以及肝硬化和肝癌等併發症嚴重。這增加了對早期診斷和定期篩檢的需求。此外，捐血的增加和強制性血液篩檢計畫的擴展也顯著提高了對肝炎診斷檢測的需求，以確保輸血安全。加強宣傳活動和全國性篩檢計畫也透過鼓勵個人，特別是高風險族群進行早期檢測，促進了市場成長。此外，即時檢測的普及提高了人們獲得快速可靠診斷的機會，尤其是在偏遠地區和資源匱乏的環境中。同時，診斷公司不斷進行產品開發和技術進步，包括引入分子檢測、自動化免疫檢測和快速診斷試劑盒，提高了檢測的準確性和效率，最終推動了肝炎檢測市場的整體成長。

5. 在肝炎檢測市場中營運的主要公司有哪些？

  • 在肝炎檢測市場中運作的主要市場參與企業包括 Abbott、F. Hoffmann-La Roche Ltd.、Diasorin SpA、Bio-Merieux、Hologic Inc.、Danaher Corporation、AdvaCare Pharma、Alpine Biomedicals Pvt Ltd.、Siemens Healthineers、SD Biosensor, Inc.、OraS Technologies Technologies Inc.、OraS TechnologiesSnos.Snos. Inc.、BTNX Inc.、ACON Laboratories, Inc.、Altona Diagnostics GmbH、Bruker Corporation、Mikrogen GmbH 和 Fortress Diagnostics。

目錄

第1章：肝炎檢測市場報告概述

  • 調查範圍
  • 市場區隔
  • 市場預期

第2章：肝炎檢測市場執行摘要

  • 市場概覽

第3章：肝炎檢測市場關鍵因素分析

  • 推動肝炎檢測市場發展的因素
    • 與肝炎感染疾病上升相關的危險因子
    • 增加捐血和血液檢測項目
    • 意識提升並加強篩檢計劃
    • 擴大就地檢驗的應用
    • 主要市場參與企業的產品開發活動日益增多
  • 限制肝炎檢測市場的因素與挑戰
    • 有交叉反應風險、感染早期階段易感性降低，或其他生物因素干擾的風險。
    • 嚴格的監管核准流程
  • 肝炎檢測市場的機遇
    • 將數位健康、遠端醫療和行動醫療技術整合到肝炎檢測中

第4章：影響分析

  • 人工智慧驅動的創新和應用
  • 美國關稅影響分析

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：波特五力模型對肝炎檢測市場的分析

第7章：肝炎檢測市場評估

  • 依產品類型
    • 試劑和試劑盒
    • 裝置
  • 透過技術
    • 酵素結合免疫吸附試驗（ELISA）
    • 快速診斷測試
    • 聚合酵素鏈鎖反應
    • 化學冷光免疫檢測
    • 其他
  • 依疾病類型
    • B型肝炎
    • C型肝炎
    • 甲型肝炎
    • 頂客
    • 戊型肝炎
  • 按測試類型
    • 抗原檢測
    • 抗體檢測
    • 核酸檢測
    • 基因分型
  • 最終用戶
    • 醫院和診所
    • 診斷檢查室
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 競爭情勢

第9章：肝炎檢測市場中的公司與產品概況

  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Diasorin SpA
  • Bio-Merieux
  • Hologic, Inc.
  • Danaher Corporation
  • AdvaCare Pharma
  • Alpine Biomedicals Pvt Ltd
  • Siemens Healthineers
  • SD Biosensor, Inc.
  • OraSure technologies, Inc.
  • Creative Technologies, Inc.
  • SSI Diagnostica A/S
  • InTec Products, Inc.
  • BTNX Inc.
  • ACON Laboratories, Inc.
  • Altona Diagnsotics GmbH
  • Bruker Corporation
  • Mikrogen GmbH
  • Fortress Diagnostics

第10章：KOL的視角

第11章 專案方法

第12章：關於 DelveInsight

第13章 免責聲明與聯絡方式

Product Code: DIMDCL0892

Hepatitis Testing Market Summary

  • The global hepatitis testing market is expected to increase from USD 3,470.08 million in 2025 to USD 5,785.24 million by 2034, reflecting strong and sustained growth.
  • The global hepatitis testing market is growing at a CAGR of 5.93% during the forecast period from 2026 to 2034.
  • The hepatitis testing market is primarily driven by the rising prevalence of hepatitis infections and their associated risk factors, such as chronic liver disease, lifestyle-related conditions, and high-risk populations. As awareness of early detection grows, healthcare providers are increasingly adopting point-of-care testing, which allows for rapid, on-site diagnosis and timely treatment decisions. Additionally, continuous product development and innovation by diagnostic companies, including the introduction of advanced molecular assays, rapid diagnostic kits, and automated testing platforms, is expanding the availability and efficiency of hepatitis testing, further fueling market growth.
  • The leading companies operating in the hepatitis testing market include Abbott, F. Hoffmann-La Roche Ltd., Diasorin S.p.A, Bio-Merieux, Hologic Inc., Danaher Corporation, AdvaCare Pharma, Alpine Biomedicals Pvt Ltd., Siemens Healthineers, SD Biosensor, Inc., OraSure Technologies, Inc., Creative Diagnostics, SSI Diagnsotica A/S, InTec Products, Inc., BTNX Inc., ACON Laboratories, Inc., Altona Diagnostics GmbH, Bruker Corporation, Mikrogen GmbH, Fortress Diagnostics and others.
  • North America's hepatitis testing market is primarily driven by the high prevalence of chronic Hepatitis B and Hepatitis C, which continues to increase the demand for early diagnosis and routine disease monitoring. In addition, technological advancements such as molecular diagnostics, automated immunoassays, and rapid point-of-care testing have significantly improved testing accuracy, efficiency, and accessibility. Mandatory blood donor screening programs and rising public awareness regarding liver health also contribute to sustained testing demand. Collectively, these factors are strengthening and accelerating the growth of the hepatitis testing market across North America.
  • In the product type segment of the hepatitis testing market, regents & kits category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Hepatitis Testing Market

  • Rising prevalence of hepatitis infections and associated risk factors: The hepatitis testing market is strongly fueled by the increasing prevalence of hepatitis infections and their serious complications, such as liver cancer and liver cirrhosis. Chronic infections with Hepatitis B and Hepatitis C can cause progressive liver damage over time, significantly raising the risk of cirrhosis and liver cancer. This growing health burden has created a critical need for early detection and routine screening, enabling timely intervention and better disease management. As a result, there is an increasing demand for advanced hepatitis diagnostic tools, including molecular assays, serological tests, and rapid diagnostic kits, which is driving the overall expansion of the hepatitis testing market globally.
  • Growth in blood donation and blood screening programs: The growth in blood donation and blood screening programs is significantly boosting the hepatitis testing market as donated blood must be thoroughly screened to prevent the transmission of infectious diseases such as hepatitis B and hepatitis C. Blood banks and transfusion centers routinely conduct mandatory screening tests to detect hepatitis antigens, antibodies, or viral nucleic acids before blood is approved for transfusion. As the number of blood donations increases due to rising healthcare needs, surgical procedures, and emergency treatments, the demand for reliable hepatitis testing methods such as ELISA, rapid diagnostic tests, and nucleic acid testing (NAT) also increases. In addition, government regulations and public health initiatives that mandate strict blood safety protocols further drive the adoption of hepatitis diagnostic kits and reagents, thereby contributing to the overall growth of the hepatitis testing market.
  • Increasing awareness and screening programs: Increasing awareness and screening programs are significantly boosting the hepatitis testing market as governments and healthcare organizations are actively promoting early detection of hepatitis infections. Public health campaigns, community screening initiatives, and national hepatitis control programs encourage people to undergo routine testing, especially high-risk populations. Early diagnosis helps in timely treatment and prevents the spread of the disease, which increases the demand for various hepatitis diagnostic tests such as ELISA, rapid tests, and molecular assays. As a result, the expansion of awareness campaigns and large-scale screening programs is driving the growth of the hepatitis testing market.
  • Increasing adoption of point-of-care testing: The growing availability of point-of-care hepatitis testing kits is making diagnostic services more accessible, particularly in developing countries and remote healthcare settings. Rapid diagnostic tests allow healthcare professionals to obtain results within minutes without requiring advanced laboratory infrastructure. This expansion of decentralized testing is helping to increase screening coverage and accelerate market growth.
  • Increase in product development activities among key market players: Diagnostic companies are continuously investing in research and innovation to develop advanced testing solutions that are faster, more accurate, and easier to use. This includes the introduction of high-sensitivity molecular assays, rapid diagnostic kits, automated testing platforms, and multiplex testing technologies. Such developments not only improve the efficiency of hepatitis detection but also expand the availability of testing options across hospitals, laboratories, and point-of-care settings. The ongoing focus on innovation by key players is thus enhancing market competitiveness and fueling the overall growth of the hepatitis testing market.

Hepatitis Testing Market Report Segmentation

This hepatitis testing market report offers a comprehensive overview of the global hepatitis testing market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Reagents & Kits and Instruments), Technology (Enzyme Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Test, Polymerase Chain Reaction (PCR), Chemiluminescence Immunoassay (CLIA), and Others), Disease Type (Hepatitis B, Heaptitis C, Hepatitis A, Hepatitis D, and Hepatitis E), Test Type (Antigen Test, Antibody Test, Nucleic Acid Test and Genotype Test), End-Users (Hospitals & Clinics, Diagnostic Laboratories, and Others), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing hepatitis testing market.

Hepatitis testing is a set of medical diagnostic procedures used to detect the presence of hepatitis viruses or liver damage caused by them. It typically involves blood tests that identify viral antigens, antibodies, or genetic material (DNA/RNA) to determine whether a person has a current, past, or chronic infection. These tests help in early diagnosis, monitoring disease progression, guiding treatment decisions, and preventing transmission of hepatitis.

The hepatitis testing market is primarily driven by the rising prevalence of hepatitis infections and their severe complications, such as liver cirrhosis and liver cancer, which has increased the need for early diagnosis and routine screening. Additionally, the growth in blood donation and mandatory blood screening programs has significantly increased the demand for hepatitis diagnostic tests to ensure the safety of blood transfusions. Increasing awareness initiatives and national screening programs are also encouraging individuals, particularly high-risk populations, to undergo early testing, thereby supporting market growth. Furthermore, the expanding adoption of point-of-care testing is improving access to rapid and reliable diagnostics, especially in remote and resource-limited settings. At the same time, continuous product development and technological advancements by diagnostic companies, including the introduction of molecular assays, automated immunoassays, and rapid diagnostic kits, are enhancing testing accuracy and efficiency, ultimately driving the overall growth of the hepatitis testing market.

What are the latest hepatitis testing market dynamics and trends?

The hepatitis testing market is driven by the rising prevalence of hepatitis B and C and the increasing demand for early diagnosis and routine monitoring.

According to the Centers for Disease Control and Prevention (2025), viral hepatitis had affected more than 300 million people globally.

Additionally, as per the same source, in 2022, 1.2 million people were newly infected with hepatitis B virus (HBV) and 1 million people were newly infected with hepatitis C virus (HCV). Approximately 254 million people were living with chronic hepatitis B, while nearly 50 million people had chronic hepatitis C. As the number of people affected by hepatitis B and C has grown, the demand for early diagnosis, routine screening, and ongoing disease monitoring has increased substantially. Rising infection rates, especially among high-risk populations, have led governments and healthcare providers to expand screening programs and implement targeted public health initiatives. Moreover, the availability of effective antiviral treatments has made early detection essential for timely intervention, further encouraging widespread testing and collectively driving the growth of the hepatitis testing market.

Moreover, India's National Viral Hepatitis Control Program, which was launched in 2018 with the mission to combat hepatitis and eliminate hepatitis C by 2030, had significantly expanded hepatitis screening and treatment efforts in the country. Reports indicated that by July 2024, the program had screened approximately 10.34 crore individuals for hepatitis B and C and had provided treatment to around 3.3 lakh patients since its inception. As the program has screened millions of individuals for hepatitis B and C, it has created substantial demand for diagnostic tests, reagents, and testing kits used in hospitals, laboratories, and community health centers. Such government-led screening programs encourage routine testing, improve disease detection rates, and expand the use of hepatitis diagnostic technologies, thereby contributing to the overall growth of the hepatitis testing market.

Furthermore, the growth in blood donation and blood screening programs is significantly boosting the hepatitis testing market because all donated blood must be carefully screened to prevent the transmission of infectious diseases such as hepatitis B and hepatitis C. According to the data provided by the World Health Organization (2026), approximately, 118.5 million blood donations were collected globally. Thus, as the number of blood donations increases worldwide, the demand for reliable hepatitis diagnostic tests, including ELISA, nucleic acid testing (NAT), and rapid diagnostic kits, also rises.

However, the increase in product development activities is further boosting the overall market of respiratory care devices. For instance, in June 2024, Cepheid announced that it had received FDA De Novo marketing authorization and Clinical Laboratory Improvement Amendments (CLIA) Waiver approval for Xpert(R) HCV, making it the only molecular test in the U.S. capable of detecting hepatitis C virus RNA directly from a human capillary whole blood (fingerstick) sample. The Xpert HCV test was performed on the GeneXpert Xpress System.

Thus, the factors mentioned above are expected to boost the overall market of hepatitis testing during the forecast period from 2026 to 2034.

However, the hepatitis testing market encounters several challenges that may hinder its growth. Technical limitations in serological assays, including cross-reactivity, low sensitivity during early infection, or interference from other biological factors, can result in inaccurate or inconclusive outcomes, impacting diagnosis and patient care. Furthermore, the rigorous regulatory approval process requiring extensive clinical validation and adherence to regional and international standards can delay product launches and increase development costs. Collectively, these factors create significant obstacles for manufacturers and healthcare providers, potentially restricting the widespread adoption and timely availability of hepatitis testing solutions.

Hepatitis Testing Market Segment Analysis

Hepatitis Testing Market by Product Type (Reagents & Kits and Instruments), Technology (Enzyme Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Test, Polymerase Chain Reaction (PCR), Chemiluminescence Immunoassay (CLIA), and Others), Disease Type (Hepatitis B, Heaptitis C, Hepatitis A, Hepatitis D, and Hepatitis E), Test Type (Antigen Test, Antibody test, Nucleic Acid Test and Genotype Test), End-Users (Hospitals & Clinics, Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

Hepatitis Testing Market Regional Analysis

North America Hepatitis Testing Market Trends

North America is expected to account for the highest proportion of 42% of the hepatitis testing market in 2025, out of all regions. This dominance is fueled by the high prevalence of hepatitis B and C, extensive screening initiatives, well-developed healthcare infrastructure, technological advancements in diagnostics, and mandatory blood donor testing.

According to the Centers for Disease Control and Prevention, in 2023, the United States had recorded 1,643 new cases of hepatitis A, 2,212 new cases of hepatitis B, and 5,538 new cases of hepatitis C. With the global rise in hepatitis B and C infections, the demand for early diagnosis, routine screening, and continuous disease monitoring has grown substantially. High infection rates, particularly among high-risk populations, have led governments and healthcare providers to expand screening programs and implement targeted public health initiatives. Furthermore, the availability of effective antiviral treatments has made early detection crucial, driving wider adoption of testing and collectively fueling growth in the hepatitis testing market.

Moreover, according to Blue Faery: The Adrienne Wilson Liver Cancer Association, in 2024 an estimated 41,630 new cases of liver cancer were reported, including 28,000 cases in men and 13,630 cases in women. Chronic infections caused by Hepatitis B and Hepatitis C are major risk factors for the development of liver cancer. Long-term viral hepatitis can lead to liver inflammation, fibrosis, and cirrhosis, increasing the risk of cancer. As a result, the growing emphasis on early diagnosis and monitoring has increased the demand for advanced diagnostic tools such as serological assays, molecular tests, and rapid diagnostic kits, thereby boosting the hepatitis testing market globally.

However, the increase in product development activities is further boosting the overall market of hepatitis testing. For instance, in June 2024, Cepheid announced that it had received FDA De Novo marketing authorization and Clinical Laboratory Improvement Amendments (CLIA) Waiver approval for Xpert(R) HCV, making it the only molecular test in the U.S. capable of detecting hepatitis C virus RNA directly from a human capillary whole blood (fingerstick) sample.

Thus, all the above-mentioned factors are anticipated to propel the market for hepatitis testing in North America during the forecast period.

Europe Hepatitis Testing Market Trends

In Europe, the hepatitis testing market is primarily driven by ongoing prevalence of hepatitis B and C infections which has heightened the demand for early detection and routine monitoring. At the same time, technological advancements including molecular diagnostics, automated immunoassays, and rapid point-of-care tests have enhanced both the accuracy and accessibility of hepatitis testing.

According to the European Centre for Disease Prevention and Control, in 2023, the European Union/European Economic Area (EU/EEA) had reported 37,766 cases of hepatitis B virus (HBV) infection, corresponding to a crude rate of 8.1 cases per 100,000 population. Of these cases, 6.3% were classified as acute, 40.5% as chronic, 46.1% as unknown, and 7.1% could not be classified. With the growing number of hepatitis B and C cases, the need for early diagnosis, regular screening, and continuous disease monitoring has risen significantly. The availability of effective antiviral treatments has further emphasized the importance of early detection, driving greater adoption of testing and, in turn, fueling the growth of the hepatitis testing market.

Moreover, according to the International Agency for Research on Cancer, the estimated number of new cases of liver and intrahepatic bile duct cancer in Europe was 91,200 in 2025 and is projected to reach 113,000 by 2045. Early detection of hepatitis infections is essential to prevent progression to severe liver diseases, including liver and bile duct cancers. Growing awareness of this link has led governments and healthcare organizations to implement large-scale screening programs, boosting demand for serological, molecular, and rapid point-of-care tests, and driving growth in the global hepatitis testing market.

Hence, all the factors mentioned above are expected to drive the market for hepatitis testing in Europe during the forecast period.

Asia-Pacific Hepatitis Testing Market Trends

In the Asia Pacific region, the hepatitis testing market is driven by the growing prevalence of hepatitis B and C infections along with increasing government initiatives aimed at early diagnosis and disease control. Moreover, the adoption of advanced diagnostic technologies such as molecular testing and rapid point-of-care assays has improved the accessibility and efficiency of hepatitis detection.

According to the Global Hepatitis Elimination Initiative, the 2022 survey report indicated that the prevalence of chronic HBV infection in Japan was estimated at 0.77%. As per the same source (2023), an estimated 7.6 million people in China were living with chronic hepatitis C. As the number of infected individuals continues to increase, the demand for early diagnosis, routine screening, and continuous disease monitoring has grown significantly. Early detection enables timely initiation of antiviral treatment and helps prevent serious complications such as liver cirrhosis and liver cancer. Consequently, the growing need for early and accurate diagnosis is accelerating the expansion of the hepatitis testing market.

Moreover, according to the International Agency for Research on Cancer, the estimated number of new cases of liver and intrahepatic bile duct cancers in Japan was 390,000 in 2025 and is projected to reach 541,000 by 2045. Long-term hepatitis infections can lead to liver inflammation, cirrhosis, and eventually cancer, which has increased the need for early detection and routine screening of hepatitis viruses. As a result, healthcare providers increasingly conduct hepatitis testing to identify infected individuals at an early stage and monitor disease progression, thereby escalating the overall market of hepatitis testing across the region.

However, the increase in product development activities is further boosting the overall market of hepatitis testing. For example, in October 2025, Reszon Diagnostics International, a subsidiary of Hextar Healthcare and manufacturer of innovative rapid diagnostic tests, launched the RESZON HBsAg Rapid Test commercially. The test provided a fast and reliable method for detecting the Hepatitis B surface antigen (HBsAg) in serum, plasma, or whole-blood samples.

Thus, the factors mentioned above are expected to boost the market of hepatitis testing across the Asia-Pacific region.

Who are the major players in the hepatitis testing market?

The following are the leading companies in the hepatitis testing market. These companies collectively hold the largest market share and dictate industry trends.

  • Abbott
  • F. Hoffmann-La Roche Ltd
  • DiaSorin S.p.A
  • Bio-Merieux
  • Hologic, Inc.
  • Danaher Corporation
  • AdvaCare Pharma
  • Alpine Biomedicals Pvt Ltd
  • Siemens Healthineers
  • SD Biosensor, Inc.
  • OraSure Technologies, Inc.
  • Creative Diagnostics
  • SSI Diagnostica A/S
  • InTec Products, Inc
  • BTNX Inc.
  • ACON Laboratories, Inc.
  • Altona Diagnostics GmbH
  • Bruker Corporation
  • Mikrogen GmbH
  • Fortress Diagnostics
  • Others

How is the competitive landscape shaping the hepatitis testing market?

The competitive landscape of the hepatitis testing market is shaped by the presence of a mix of global diagnostics leaders and emerging regional players, all striving to innovate and expand their market reach. Established companies such as Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Bio-Rad Laboratories dominate through extensive product portfolios that include ELISA kits, molecular assays, and rapid point-of-care tests, supported by strong distribution networks and regulatory approvals across multiple regions. Competition is intensified by continuous technological advancements, with companies investing heavily in next-generation diagnostics that offer higher sensitivity, faster turnaround times, and automation to meet growing clinical demands. Additionally, strategic collaborations, mergers, acquisitions, and partnerships are increasingly being used to expand geographic presence, strengthen R&D capabilities, and improve access to emerging markets. Smaller or regional players focus on niche segments such as affordable rapid tests or specialized molecular kits, creating diverse options for end-users. This dynamic competitive environment drives innovation, improves testing accuracy, broadens product availability, and ultimately shapes the growth trajectory of the global hepatitis testing market.

Overall, the hepatitis testing market is witnessing robust competition, where innovation, compliance, and strategic growth initiatives are the primary factors enabling companies to differentiate themselves, capture market share, and meet the evolving needs of healthcare providers globally.

Recent Developmental Activities in the Hepatitis Testing Market

  • In December 2025, Altona launched the AltoStar(R) HDV RT-PCR Kit 1.5 (CE-IVD), completing its CE-IVD PCR portfolio for all five hepatitis viruses.
  • In August 2025, HiMedia Laboratories received Central Drugs Standard Control Organisation (CDSCO) approval in India for its Hi-PCR(R) Hepatitis B and C molecular diagnostic kits (quantitative), marking a significant milestone for the company's hepatitis testing portfolio.

Hepatitis Testing Market Segmentation

  • Hepatitis Testing by Product Type Exposure
  • Reagents & Kits
  • Instruments
  • Hepatitis Testing Technology Exposure
  • Enzyme Linked Immunosorbent Assay (ELISA)
  • Rapid Diagnostic Test
  • Chemiluminescence Immunoassay (CLIA)
  • Polymerase Chain Reaction (PCR)
  • Others
  • Hepatitis Testing Disease Type Exposure
  • Hepatitis B
  • Hepatitis C
  • Hepatitis A
  • Hepatitis D
  • Hepatitis E
  • Hepatitis Testing Test Type Exposure
  • Antigen Test
  • Antibody Test
  • Nucleic Acid
  • Genotype Test
  • Hepatitis Testing End-Users Exposure
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others
  • Hepatitis Testing Geography Exposure
  • North America Hepatitis Testing Market
  • United States Hepatitis Testing Market
  • Canada Hepatitis Testing Market
  • Mexico Hepatitis Testing Market
  • Europe Hepatitis Testing Market
  • United Kingdom Hepatitis Testing Market
  • Germany Hepatitis Testing Market
  • France Hepatitis Testing Market
  • Italy Hepatitis Testing Market
  • Spain Hepatitis Testing Market
  • Rest of Europe Hepatitis Testing Market
  • Asia-Pacific Hepatitis Testing Market
  • China Hepatitis Testing Market
  • Japan Hepatitis Testing Market
  • India Hepatitis Testing Market
  • Australia Hepatitis Testing Market
  • South Korea Hepatitis Testing Market
  • Rest of Asia-Pacific Hepatitis Testing Market
  • Rest of the World Hepatitis Testing Market
  • South America Hepatitis Testing Market
  • Middle East Hepatitis Testing Market
  • Africa Hepatitis Testing Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are increasingly influencing the hepatitis testing market by enhancing diagnostic accuracy, operational efficiency, and clinical decision-making. Artificial intelligence (AI) and machine learning algorithms can analyze complex data from imaging, laboratory results, and patient records to identify patterns that may be difficult for human interpretation alone. In hepatitis testing, AI supports improved interpretation of molecular and serological assay data, reducing false positives and negatives and enabling earlier detection of infection. AI also accelerates workflow automation in high-volume laboratory environments by optimizing sample processing, result validation, and quality control, which reduces turnaround times and operational costs. When integrated with next-generation diagnostic platforms, such as digital immunoassays and PCR systems, AI tools help laboratories tailor testing protocols based on patient history and risk factors, improving personalized diagnostics and treatment planning. Additionally, AI facilitates predictive analytics and population health management by identifying trends in hepatitis incidence and testing patterns, enabling health systems to allocate resources more effectively and target screening programs to high-risk groups. AI-driven software can also support telemedicine and remote testing interpretations, expanding access in underserved or resource-limited regions. Overall, the integration of AI into the hepatitis testing ecosystem is enhancing efficiency, accuracy, and scalability, positioning AI as a transformative factor that is likely to support future market growth and innovation.

U.S. Tariff Impact Analysis on Hepatitis Testing Market:

The U.S. tariff impact on the hepatitis testing market centers on how broader trade duties on imported medical and diagnostic products can influence costs, supply chains, and competitive dynamics within the in vitro diagnostics (IVD) sector that includes hepatitis testing kits and related reagents. Since many diagnostic components and complete test kits are produced outside the United States, tariffs on imports-ranging from baseline duties to elevated trade penalties on goods from key manufacturing hubs-can increase the cost of goods sold for companies that rely on foreign production, potentially prompting higher prices for laboratories, clinics, and patients. Diagnostic manufacturers may respond by absorbing costs, relocating manufacturing to the U.S., or shifting supply chains, which could influence product pricing and availability in the hepatitis testing segment. Higher input costs and supply chain disruptions caused by tariffs can also strain operational budgets of healthcare providers by making essential supplies more expensive and less predictable to source, which in turn may affect testing volumes and overall market growth dynamics. Companies with primarily domestic manufacturing could benefit if imported competitors face tariff-induced cost increases, while ongoing tariff uncertainty may deter investment and complicate long-term planning for both suppliers and buyers in the hepatitis testing market.

How This Analysis Helps Clients

  • Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
  • Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
  • Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
  • Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the hepatitis testing market report study

  • Market size analysis for the current hepatitis testing market size (2025), and market forecast for 8 years (2026 to 2034)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the hepatitis testing market.
  • Various opportunities available for the other competitors in the hepatitis testing market space.
  • What are the top-performing segments in 2025? How these segments will perform in 2034?
  • Which are the top-performing regions and countries in the current hepatitis testing market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for the hepatitis testing market growth in the future?

Frequently Asked Questions for the Hepatitis Testing Market

1. What is the growth rate of the hepatitis testing market?

  • The hepatitis testing market is estimated to grow at a CAGR of 5.93% during the forecast period from 2026 to 2034.

2. What is the market for needle safety devices?

  • The global hepatitis testing market is expected to increase from USD 3,470.08 million in 2025 to USD 5,785.24 million by 2034, reflecting strong and sustained growth.

3. Which region has the highest share in the hepatitis testing market?

  • North America's hepatitis testing market is driven by the high prevalence of chronic Hepatitis B and C, increasing the need for early diagnosis and routine monitoring. Technological advancements in molecular diagnostics, automated immunoassays, and rapid tests, along with mandatory blood screening and growing public awareness, are enhancing accuracy, accessibility, and demand, collectively fueling market growth.

4. What are the drivers for the hepatitis testing market?

  • The hepatitis testing market is primarily driven by the rising prevalence of hepatitis infections and their severe complications, such as liver cirrhosis and liver cancer, which has increased the need for early diagnosis and routine screening. Additionally, the growth in blood donation and mandatory blood screening programs has significantly increased the demand for hepatitis diagnostic tests to ensure the safety of blood transfusions. Increasing awareness initiatives and national screening programs are also encouraging individuals, particularly high-risk populations, to undergo early testing, thereby supporting market growth. Furthermore, the expanding adoption of point-of-care testing is improving access to rapid and reliable diagnostics, especially in remote and resource-limited settings. At the same time, continuous product development and technological advancements by diagnostic companies, including the introduction of molecular assays, automated immunoassays, and rapid diagnostic kits, are enhancing testing accuracy and efficiency, ultimately driving the overall growth of the hepatitis testing market.

5. Who are the key players operating in the hepatitis testing market?

  • Some of the key market players operating in the hepatitis testing market include Abbott, F. Hoffmann-La Roche Ltd., Diasorin S.p.A, Bio-Merieux, Hologic Inc., Danaher Corporation, AdvaCare Pharma, Alpine Biomedicals Pvt Ltd., Siemens Healthineers, SD Biosensor, Inc., OraSure Technologies, Inc., Creative Diagnostics., SSI Diagnsotica A/S, InTec Products, Inc., BTNX Inc., ACON Laboratories, Inc., Altona Diagnostics GmbH, Bruker Corporation, Mikrogen GmbH, Fortress Diagnostics and others.

Table of Contents

1. Hepatitis Testing Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Hepatitis Testing Market Executive Summary

  • 2.1 Market at Glance

3. Hepatitis Testing Market Key Factors Analysis

  • 3.1 Hepatitis Testing Market Drivers
    • 3.1.1 Rising prevalence of hepatitis infections and associated risk factors
    • 3.1.2 Growth in blood donation and blood screening programs
    • 3.1.3 Increasing awareness and screening programs
    • 3.1.4 Increasing adoption of point-of-care testing
    • 3.1.5 Increase in product development activities among key market players
  • 3.2 Hepatitis Testing Market Restraints and Challenges
    • 3.2.1 Risk of cross-reactivity, low sensitivity during early infection, or interference from other biological factors
    • 3.2.2 Stringent regulatory approval process
  • 3.3 Hepatitis Testing Market Opportunity
    • 3.3.1 Integration of digital health, telemedicine and mobile health technologies in hepatitis testing

4. Impact Analysis

  • 4.1 AI-Powered Innovations and Applications
  • 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

  • 5.1 The United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Hepatitis Testing Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Hepatitis Testing Market Assessment

  • 7.1 By Product Type
    • 7.1.1 Reagents & Kits
    • 7.1.2 Instruments
  • 7.2 By Technology
    • 7.2.1 Enzyme Linked immunosorbent Assay (ELISA)
    • 7.2.2 Rapid Diagnostic Test
    • 7.2.3 Polymerase Chain Reaction
    • 7.2.4 Chemiluminescence Immunoassay
    • 7.2.5 Others
  • 7.3 By Disease Type
    • 7.3.1 Hepatitis B
    • 7.3.2 Hepatitis C
    • 7.3.3 Hepatitis A
    • 7.3.4 Hepatitis D
    • 7.3.5 Hepatitis E
  • 7.4 By Test Type
    • 7.4.1 Antigen Test
    • 7.4.2 Antibody Test
    • 7.4.3 Nucleic Acid Test
    • 7.4.4 Genotype Test
  • 7.5 By End-Users
    • 7.5.1 Hospitals & Clinics
    • 7.5.2 Diagnostic Laboratories
    • 7.5.3 Others
  • 7.6 By Geography
    • 7.6.1 North America
      • 7.6.1.1 United States Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.1.2 Canada Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.1.3 Mexico Hepatitis Testing Market Size in USD million (2023-2034)
    • 7.6.2 Europe
      • 7.6.2.1 France Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.2.2 Germany Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.2.3 United Kingdom Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.2.4 Italy Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.2.5 Spain Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.2.6 Rest of Europe Hepatitis Testing Market Size in USD million (2023-2034)
    • 7.6.3 Asia-Pacific
      • 7.6.3.1 China Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.3.2 Japan Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.3.3 India Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.3.4 Australia Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.3.5 South Korea Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.3.6 Rest of Asia-Pacific Hepatitis Testing Market Size in USD million (2023-2034)
    • 7.6.4 Rest of the World (RoW)
      • 7.6.4.1 Middle East Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.4.2 Africa Hepatitis Testing Market Size in USD million (2023-2034)
      • 7.6.4.3 South America Hepatitis Testing Market Size In USD Million (2023-2034)

8. Competitive Landscape

9. Hepatitis Testing Market Company and Product Profiles

  • 9.1 Abbott
    • 9.1.1 Company Overview
    • 9.1.2 Company Snapshot
    • 9.1.3 Financial Overview
    • 9.1.4 Product Listing
    • 9.1.5 Entropy
  • 9.2 F. Hoffmann-La Roche Ltd.
    • 9.2.1 Company Overview
    • 9.2.2 Company Snapshot
    • 9.2.3 Financial Overview
    • 9.2.4 Product Listing
    • 9.2.5 Entropy
  • 9.3 Diasorin S.p.A
    • 9.3.1 Company Overview
    • 9.3.2 Company Snapshot
    • 9.3.3 Financial Overview
    • 9.3.4 Product Listing
    • 9.3.5 Entropy
  • 9.4 Bio-Merieux
    • 9.4.1 Company Overview
    • 9.4.2 Company Snapshot
    • 9.4.3 Financial Overview
    • 9.4.4 Product Listing
    • 9.4.5 Entropy
  • 9.5 Hologic, Inc.
    • 9.5.1 Company Overview
    • 9.5.2 Company Snapshot
    • 9.5.3 Financial Overview
    • 9.5.4 Product Listing
    • 9.5.5 Entropy
  • 9.6 Danaher Corporation
    • 9.6.1 Company Overview
    • 9.6.2 Company Snapshot
    • 9.6.3 Financial Overview
    • 9.6.4 Product Listing
    • 9.6.5 Entropy
  • 9.7 AdvaCare Pharma
    • 9.7.1 Company Overview
    • 9.7.2 Company Snapshot
    • 9.7.3 Financial Overview
    • 9.7.4 Product Listing
    • 9.7.5 Entropy
  • 9.8 Alpine Biomedicals Pvt Ltd
    • 9.8.1 Company Overview
    • 9.8.2 Company Snapshot
    • 9.8.3 Financial Overview
    • 9.8.4 Product Listing
    • 9.8.5 Entropy
  • 9.9 Siemens Healthineers
    • 9.9.1 Company Overview
    • 9.9.2 Company Snapshot
    • 9.9.3 Financial Overview
    • 9.9.4 Product Listing
    • 9.9.5 Entropy
  • 9.10 SD Biosensor, Inc.
    • 9.10.1 Company Overview
    • 9.10.2 Company Snapshot
    • 9.10.3 Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5 Entropy
  • 9.11 OraSure technologies, Inc.
    • 9.11.1 Company Overview
    • 9.11.2 Company Snapshot
    • 9.11.3 Financial Overview
    • 9.11.4 Product Listing
    • 9.11.5 Entropy
  • 9.12 Creative Technologies, Inc.
    • 9.12.1 Company Overview
    • 9.12.2 Company Snapshot
    • 9.12.3 Financial Overview
    • 9.12.4 Product Listing
    • 9.12.5 Entropy
  • 9.13 SSI Diagnostica A/S
    • 9.13.1 Company Overview
    • 9.13.2 Company Snapshot
    • 9.13.3 Financial Overview
    • 9.13.4 Product Listing
    • 9.13.5 Entropy
  • 9.14 InTec Products, Inc.
    • 9.14.1 Company Overview
    • 9.14.2 Company Snapshot
    • 9.14.3 Financial Overview
    • 9.14.4 Product Listing
    • 9.14.5 Entropy
  • 9.15 BTNX Inc.
    • 9.15.1 Company Overview
    • 9.15.2 Company Snapshot
    • 9.15.3 Financial Overview
    • 9.15.4 Product Listing
    • 9.15.5 Entropy
  • 9.16 ACON Laboratories, Inc.
    • 9.16.1 Company Overview
    • 9.16.2 Company Snapshot
    • 9.16.3 Financial Overview
    • 9.16.4 Product Listing
    • 9.16.5 Entropy
  • 9.17 Altona Diagnsotics GmbH
    • 9.17.1 Company Overview
    • 9.17.2 Company Snapshot
    • 9.17.3 Financial Overview
    • 9.17.4 Product Listing
    • 9.17.5 Entropy
  • 9.18 Bruker Corporation
    • 9.18.1 Company Overview
    • 9.18.2 Company Snapshot
    • 9.18.3 Financial Overview
    • 9.18.4 Product Listing
    • 9.18.5 Entropy
  • 9.19 Mikrogen GmbH
    • 9.19.1 Company Overview
    • 9.19.2 Company Snapshot
    • 9.19.3 Financial Overview
    • 9.19.4 Product Listing
    • 9.19.5 Entropy
  • 9.20 Fortress Diagnostics
    • 9.20.1 Company Overview
    • 9.20.2 Company Snapshot
    • 9.20.3 Financial Overview
    • 9.20.4 Product Listing
    • 9.20.5 Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1: Hepatitis Testing Market in Global (2023-2034)
  • Table 2: Hepatitis Testing Market in Global by Product Type (2023-2034)
  • Table 3: Hepatitis Testing Market in Global by Technology (2023-2034)
  • Table 4: Hepatitis Testing Market in Global by Disease Type (2023-2034)
  • Table 5: Hepatitis Testing Market in Global by Test Type (2023-2034)
  • Table 6: Hepatitis Testing Market in Global by End-Users (2023-2034)
  • Table 7: Hepatitis Testing Market in Global by Geography (2023-2034)
  • Table 8: Hepatitis Testing Market in North America (2023-2034)
  • Table 9: Hepatitis Testing Market in the United States (2023-2034)
  • Table 10: Hepatitis Testing Market in Canada (2023-2034)
  • Table 11: Hepatitis Testing Market in Mexico (2023-2034)
  • Table 12: Hepatitis Testing Market in Europe (2023-2034)
  • Table 13: Hepatitis Testing Market in France (2023-2034)
  • Table 14: Hepatitis Testing Market in Germany (2023-2034)
  • Table 15: Hepatitis Testing Market in United Kingdom (2023-2034)
  • Table 16: Hepatitis Testing Market in Italy (2023-2034)
  • Table 17: Hepatitis Testing Market in Spain (2023-2034)
  • Table 18: Hepatitis Testing Market in the Rest of Europe (2023-2034)
  • Table 19: Hepatitis Testing Market in Asia-Pacific (2023-2034)
  • Table 20: Hepatitis Testing Market in China (2023-2034)
  • Table 21: Hepatitis Testing Market in Japan (2023-2034)
  • Table 22: Hepatitis Testing Market in India (2023-2034)
  • Table 23: Hepatitis Testing Market in Australia (2023-2034)
  • Table 24: Hepatitis Testing Market in South Korea (2023-2034)
  • Table 25: Hepatitis Testing Market in Rest of Asia-Pacific (2023-2034)
  • Table 26: Hepatitis Testing Market in the Rest of the World (2023-2034)
  • Table 27: Hepatitis Testing Market in the Middle East (2023-2034)
  • Table 28: Hepatitis Testing Market in Africa (2023-2034)
  • Table 29: Hepatitis Testing Market in South America (2023-2034)
  • Table 30: Competitive Landscape

List of Figures

  • Figure 1: Hepatitis Testing Market Drivers
  • Figure 2: Hepatitis Testing Market Restraints
  • Figure 3: Hepatitis Testing Market Opportunities
  • Figure 4: AI-Powered Innovations in Hepatitis Testing Market
  • Figure 5: US Tariff Impact on Hepatitis Testing Market
  • Figure 6: Regulatory Analysis (US, EU, Japan, China)
  • Figure 7: Porter's Five Forces Analysis
  • Figure 8: Competitive Analysis
  • Figure 9: Hepatitis Testing Market in Global (2023-2034)
  • Figure 10: Hepatitis Testing Market in Global by Product Type (2023-2034)
  • Figure 11: Hepatitis Testing Market in Global by Technology (2023-2034)
  • Figure 12: Hepatitis Testing Market in Global by Disease Type (2023-2034)
  • Figure 13: Hepatitis Testing Market in Global by Test Type (2023-2034)
  • Figure 14: Hepatitis Testing Market in Global by End-Users (2023-2034)
  • Figure 15: Hepatitis Testing Market in Global by Geography (2023-2034)
  • Figure 16: Hepatitis Testing Market in North America (2023-2034)
  • Figure 17: Hepatitis Testing Market in the United States (2023-2034)
  • Figure 18: Hepatitis Testing Market in Canada (2023-2034)
  • Figure 19: Hepatitis Testing Market in Mexico (2023-2034)
  • Figure 20: Hepatitis Testing Market in Europe (2023-2034)
  • Figure 21: Hepatitis Testing Market in France (2023-2034)
  • Figure 22: Hepatitis Testing Market in Germany (2023-2034)
  • Figure 23: Hepatitis Testing Market in United Kingdom (2023-2034)
  • Figure 24: Hepatitis Testing Market in Italy (2023-2034)
  • Figure 25: Hepatitis Testing Market in Spain (2023-2034)
  • Figure 26: Hepatitis Testing Market in the Rest of Europe (2023-2034)
  • Figure 27: Hepatitis Testing Market in Asia-Pacific (2023-2034)
  • Figure 28: Hepatitis Testing Market in China (2023-2034)
  • Figure 29: Hepatitis Testing Market in Japan (2023-2034)
  • Figure 30: Hepatitis Testing Market in India (2023-2034)
  • Figure 31: Hepatitis Testing Market in Australia (2023-2034)
  • Figure 32: Hepatitis Testing Market in South Korea (2023-2034)
  • Figure 33: Hepatitis Testing Market in Rest of Asia-Pacific (2023-2034)
  • Figure 34: Hepatitis Testing Market in the Rest of the World (2023-2034)
  • Figure 35: Hepatitis Testing Market in the Middle East (2023-2034)
  • Figure 36: Hepatitis Testing Market in Africa (2023-2034)
  • Figure 37: Hepatitis Testing Market in South America (2023-2034)
  • Figure 38: Competitive Landscape